Overview

A Study to Assess the Phamacokinetics of BV100 in Participants With Varying Degrees of Hepatic Impairment

Status:
Recruiting
Trial end date:
2023-03-30
Target enrollment:
Participant gender:
Summary
To investigate the pharmacokinetics (PK) of rifabutin in subjects with hepatic impairment after single intravenous (IV) infusion of BV100
Phase:
Phase 1
Details
Lead Sponsor:
BioVersys AG
Collaborator:
CRU Hungary Kft